Patients with thoracic aortic dissection may qualify for new, less invasive treatment. A new treatment, approved for investigational use by the Food and Drug Administration (FDA), is available at [insert name of institution] for patients who have been diagnosed with a thoracic aortic dissection (a tearing of the body’s main blood vessel). If you meet study requirements, you could participate in the STABLE™ Clinical Trial (Study for Thoracic Aortic Type B Dissection using Endoluminal Repair), which could eliminate the need for highly invasive surgery.
To be considered for participation in the STABLE™ Clinical Trial, you must meet the following general study criteria: • 18 or older • Diagnosed with a descending thoracic aortic dissection warranting surgical intervention • Assessment performed by a study physician in compliance with the study protocol For more information about this trial, call [insert phone number].
www.thoracicaorticdissection.com